Healio

Vigorous exercise confers better quality of life in pediatric long QT syndrome

In children with long QT syndrome, vigorous exercise was linked to better physical and psychosocial quality of life compared with nonvigorous exercise, researchers reported at Heart Rhythm 2026. As ...

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1 ...
Morningstar

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...